International Journal of Clinical Pharmacy

, Volume 35, Issue 4, pp 608–612 | Cite as

Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand

  • Somsak TiamkaoEmail author
  • Jukrapope Jitpimolmard
  • Kittisak Sawanyawisuth
  • Suthipun Jitpimolmard
Research Article


Background Carbamazepine (CBZ) is broadly used for the treatment of epilepsy, neuropathic pain and other neurological diseases, owing to its effectiveness and low price. CBZ can induce Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). There are several studies that found an association between HLA-B*1502 and CBZ-induced SJS/TEN, especially in people of Thai origin. In Thailand the prevalence of HLA-B*1502 was found to be in the range 8.1–14 %. Objective This study aimed to determine if screening for HLA-B*1502 in Thai patients who were to receive CBZ is cost effective. Setting Srinagarind Hospital, Khon Kaen University, Thailand. Method A comparison between treatment cost of CBZ induced SJS/TEN and the HLAB*1502 screening costs in the Thai population. Main outcome measure Comparison of the costs of treatment of CBZ induced SJS/TEN and costs of HLA-B*1502 screening test. Results When persons having the HLA-B*1502 allele receive CBZ, the chance of developing SJS/TEN is as high as 88.1 %, while persons without the HLA-B*1502 allele do not develop SJS/TEN. Therefore, a model was calculated to compare the cost of treatment between HLA-B*1502 testing before giving CBZ and if the patients were not tested for HLAB*1502. It was found that screening 100 patients before giving CBZ would save an amount of 98,549.94 baht per 100 cases of CBZ-prescribed patients. Conclusion The screening for HLA-B*1502 allele before giving carbamazepine is cost effective. The results of the present study may also apply to other populations if the HLA-B*1502 frequency is high enough.


Carbamazepine Cost-effectiveness Epidermal Necrolysis HLA-B*1502 Stevens–Johnson syndrome Screening Toxic epidermal necrolysis 



The authors would like to thank Prof. James A. Will (University of Wisconsin) for reviewing and English proofreading of the manuscript.



Conflicts of interest



  1. 1.
    Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor. Malays Int J Dermatol. 2010;49(7):834–41.Google Scholar
  2. 2.
    Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;16(5):39.CrossRefGoogle Scholar
  3. 3.
    Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.PubMedCrossRefGoogle Scholar
  4. 4.
    Zhang Y, Wang J, Zhao LM, Peng W, Shen GQ, Xue L, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol. 2010;67(9):885–7.CrossRefGoogle Scholar
  5. 5.
    Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia. 2010;51(5):926–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Eng J Med. 2011;364(12):1126–33.CrossRefGoogle Scholar
  8. 8.
    Chang CC, Too CL, Murad S, Hussein SH. (2011) Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multiethnic Malaysian population. Int J Dermatol. 2011;50(2):221–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Wu XT, Hu FY, An DM, Yan B, Jiang X, Kwan P, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLAB*1502 allele among patients in central China. Epilepsy Behav. 2010;19(3):405–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Romphruk AV, Romphruk A, Kongmaroeng C, Klumkrathok K, Paupairoj C, Leelayuwat C. HLA class I and II alleles and haplotypes in ethnic Northeast Thais. Tissue Antigens. 2010;75(6):701–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49(2):542–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Locharernkul C, Shotelersuk V, Hirankarn N. HLA-B* 1502 screening: time to clinical practice. Epilepsia. 2010;51(5):936–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Thavichachart N, Intoh P, Thavichachart T, Meksupa O, Tangwongchai S, Sughondhabirom A. Epidemiological survey of mental disorders and knowledge attitude practice upon mental health among people in Bangkok Metropolis. J Med Assoc Thai. 2001;84(S1):S118–26.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Somsak Tiamkao
    • 1
    Email author
  • Jukrapope Jitpimolmard
    • 1
  • Kittisak Sawanyawisuth
    • 1
  • Suthipun Jitpimolmard
    • 1
  1. 1.Department of Medicine, Faculty of MedicineKhon Kaen UniversityKhon KaenThailand

Personalised recommendations